Supplementary Table S3. Response to platinum-based chemotherapy according to p-BRCA mutations and LOH within MSS subgroup

Response	p-BRCA mut	tations and LOH status wi	and LOH status within MSS subgroup	
	LOH+	LOH-	Wild	
Complete response	1 (6.3)	0	5 (3.5)	.005a
Partial response	15 (93.8)	6 (50.0)	82 (57.7)	
Stable disease	0	5 (41.7)	48 (33.8)	
Progressive disease	0	1 (8.3)	7 (4.9)	
Total	16	12	142	

Values are presented as number (%).

p-BRCA, pathogenic or likely pathogenic mutations involving *BRCA1* or *BRCA2*; LOH, loss of heterozygosity; MSS, microsatellite stable.

^aKruskal-Wallis test.